We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

MIMETAS Launches OrganoPlate UniFlow Technology at SLAS 2025

Cell culture.
Credit: MIMETAS.
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

MIMETAS, has launched OrganoPlate UniFlow (UF), the first commercially available unidirectional, gravity-driven pumpless flow system for drug discovery and disease research. This innovative platform debuts at SLAS 2025 as a key addition to MIMETAS’ service portfolio.


OrganoPlate UF addresses challenges in traditional flow systems by enabling physiologically accurate tissue models that replicate natural biological conditions. With unidirectional, gravity-driven flow, this system eliminates the need for external pumps, simplifying operation while enhancing model accuracy. Supporting up to 512 chips in a single setup, the technology is ideal for rigorous scientific studies and large-scale screening, accelerating research without compromising biological relevance.

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

Key Features of OrganoPlate UF Technology:

  • Unidirectional flow: Improves modeling of vasculature for studies in cardiovascular, oncological, and immunological research.
  • Pump-free, gravity-driven design: Simplifies operations while mimicking natural flow conditions.


Scalable and compatible: Operates seamlessly with standard liquid handling and imaging equipment, enabling high-throughput analysis of hundreds or thousands of tissue models.


Stable, long-term culture: Supports extended culture of complex tissues for chronic disease and therapeutic studies.

Driving Innovation in Drug Discovery

“The MIMETAS OrganoPlate has led the field in microphysiological cell culture for over 12 years,” said Bas Trietsch, MIMETAS co-founder. “With UniFlow, we’ve achieved unidirectional flow that mimics blood circulation while maintaining the ease of use, compatibility, and throughput that make our technology exceptional.”


OrganoPlate UF is already integrated into MIMETAS’ liver, lung, brain, vasculature, and tumor models and is used to study immunological, cardiovascular, and metabolic diseases, as well as cancer. This platform is now available as part of MIMETAS’ service offerings.